Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533019) titled 'A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo' on April 9.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Vitiligo
Non-Segmental Vitiligo (NSV)
Intervention:
Drug: LY4005130
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 14, 2026
Target Sample Size: 60
Countries of Recruitment:
United States
Belgium
Canada
China
Poland
Belgium
Canada
China
Poland
United States
To...